Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press38110.36691/RJA381ArticlesСтатьиResearch ArticleLevocetirizine in clinical practice of allergistЛевоцетиризин в клинической практике врача-аллерго- логаElisyutinaO GЕлисютинаОльга Гурьевнаel-olga@yandex.ruShtyrbulO VШтырбулО ВInstitute of ImmunologyФГБУ «ГНЦ Институт иммунологии» ФМБА России15062016133NO3 (2016)№3 (2016)495010032020Copyright ©; 2016, Pharmarus Print MediaCopyright ©; 2016, Фармарус Принт Медиа2016Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/381

Levocetirizine is an effective H1-blocker of histamine receptors in complex treatment of various allergic diseases. The article presents the literature data and own observational data on clinical efficacy and safety of levocetirizine in the treatment of allergic diseases such as allergic rhinitis, bronchial asthma, allergic dermatoses.

Левоцетиризин является эффективным блокатором H1-рецепторов гистамина в комплексном лечении больных различными аллергическими заболеваниями. В статье приведены литературные данные о клинической эффективности и безопасности применения левоцетиризина в лечении таких аллергических заболеваний, как аллергический ринит, бронхиальная астма, аллергодерматозы. Также приведены данные собственных наблюдений.

levocetirizinesuprastinexantihistamine therapyH-histamine receptorsallergic rhinitisbronchial asthmaallergic dermatosesлевоцетиризинсупрастинексантигистаминная терапияблокаторы Н-гистаминовых рецептороваллергический ринитбронхиальная астмааллергодерматозыАллергология и иммунология: национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, 656 с.Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, v 108, p. 147-334.Church M., Church D. Pharmacology of antihistamines. Indian J. Dermatol. 2013, v. 58, p. 219-224.Takeshita K., Sakai K., Bacon K.B., Gantner B. Critical role of histamine H4-receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J. Pharmacol. Exp. Ther. 2003, v. 307, p. 1072-1078.Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 252 с.Holgate S.T., Canonica G.W., Simons F.E. et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clinical & Experimental Allergy. 2003, v. 33, p. 1305-1324.Gillard M., van der Perren C., Moguilevsky N. et al. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol. Pharmacol. 2002, v. 61, p. 391-399.Molimard M., Diquet B., Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 2004, v. 18, p. 399-411.Tillement J.P The advantages for an H1-antihistamine of a low volume of distribution. Allergy. 2000, v. 55, p. 17-21.Simons F.E.R., Simons K.J. H1-antihistamines: Current Status and Future Directions. World Allergy Organ J. 2008, v. 1, p. 145-155.Хаитов Р.М., Ильина Н.И. Аллергология. Федеральные клинические рекомендации. М., «Фармарус Принт Медиа». 2014, 124 с.Bousquet J., Van Cauwenberge P., Bachert C. et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI). Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003, v. 58, p. 192-197.Deruaz C., Leimgruber A., Berney M. et al. Better protects than desloratadine in a nasal provocation with allergen. J. Allergy Clin. Immunol. 2004, v. 113, p. 669-676.Grant A.J., Riethuisen J.M., Moulaert B., De Vos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma Immunol. 2002, v. 88, p. 190-197.Jorissen M., Bertrand B., Stiels B., Vandenbulcke K. Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT. 2006, v. 2, p. 55-62.Bachert C., Bousquet J., Canonica G.W et al. XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J. Allergy Clin. Immunol. 2004, v. 114, p. 838-844.De Blic J., Wahn U., Billard E. et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr. Allergy Immunol. 2005, v. 16, p. 267-275.Simons F.E. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol. 2007, v. 18, p. 535-542.Bocçan C.I., Bujor A.I., Miron N. et al. In vivo anti-inflammatory effect of H1-antihistamines in allergic rhinitis: A randomized clinical trial. Balkan Med. J. 2015, v. 32, p. 352-358.Zuberbier T., Aberer W., Asero R. et al. The EaACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diag nosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, p. 868-887.Российский национальный согласительный документ «Крапивница и ангиоотек». Рекомендации для практических врачей. Под общей редакцией чл.-корр. РАМН, проф. И.С. Гущина. M., «Фармарус Принт Медиа». 2007, 128 с.Kapp A., Pichler W.J. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int. J. Dermatol. 2005, v. 45, p. 469-474.Potter P.C., Kapp A., Maurer M. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009, v. 64, p. 596-604.Sharma M., Bennett C., Carter B., Cohen S.N. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review. J. Am. Acad. Dermatol. 2015, v. 73, p. 710-716.Ring J., Alomar A., Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1045-1060.Гребенченко Е.И., Гущин И.С., Феденко Е.С. Механизм кожного зуда при атопическом дерматите. Рос. Аллергол. Журн. 2009, № 3, с. 3-11.Klein P.A., Clark R.A. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol. 1999, v. 135, p. 1522-1525.Diepgen T.L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunolog. 2002, v. 13, p. 278-286.Henz B., Metzenauer P., O’Keefe E., Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy. 1998, v. 53, p. 180-183.Van Zuuren E., Apfelbacher C., Fedorowicz Z. et al. No high level evidence to support the use of oral H1-antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst. Rev. 2014, v. 13, p. 3-25.Yamanaka K., Motomura E., Noro Y. et al. Olopatadine, a non-sedating H1-antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis. Exp. Dermatol. 2015, v. 24, p. 227-229.Church M.K., Maurer M. H1-antihistamines and itch in atopic dermatitis. Exp. Dermatol. 2015, v. 24, p. 332-333.Weisshaar E., Jacek C., Szepietowski U.D. et al. European Guideline on chronic pruritis. Acta Derm. Venereol. 2012, v. 92, p. 563-581.Елисютина О.Г., Феденко Е.С., Федоскова Т.Г., Лусс Л.В. Эффективность терапии левоцетиризином больных с аллергодерматозами. Рос. Аллергол. Журн. 2012, № 5, с. 69-75.